EDTXF Stock Chart & Stats
$0.96
<$0.01(0.81%)
At close: 4:00 PM EDT
$0.96
<$0.01(0.81%)
Day’s Range― - ―
52-Week Range$0.81 - $1.27
Previous CloseN/A
Volume419.00
Average Volume (3M)12.94K
Market Cap
$281.79M
Enterprise Value$411.25
Total Cash (Recent Filing)$803.00K
Total Debt (Recent Filing)$25.68M
Price to Earnings (P/E)―
Beta-0.07
Next Earnings
Nov 06, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding293,554,000
10 Day Avg. Volume8,859
30 Day Avg. Volume12,935
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)-5.93
Price to Sales (P/S)169.36
P/FCF Ratio-42.55
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$2.53Price Target Upside163.32% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.02
Revenue Forecast (FY)$2.01M
Bulls Say, Bears Say
Bulls Say
FDA PMA ProgressFDA acceptance reduces a major regulatory barrier for PMX and supports a future commercialization pathway. If approval is achieved, the milestone could materially expand access to Spectral’s lead therapy.
Clinical SupportSupportive follow-up data can strengthen the clinical case for PMX, improve credibility with regulators and providers, and support adoption. This is particularly important for a therapy used in high-risk critical-care settings.
Integrated PlatformCombining a targeted endotoxin-removal therapy with a diagnostic intended to identify suitable patients creates an integrated product strategy. This may improve clinical positioning and differentiate the platform if validation and approval succeed.
Bears Say
Balance Sheet StressNegative equity, rising debt, and a very small asset base leave little financial cushion against further losses. The resulting solvency risk may constrain investment, weaken negotiating leverage, and increase dependence on external funding.
Persistent Cash BurnSustained operating and free-cash-flow deficits indicate that current activities do not fund the business. Continued clinical, regulatory, and commercialization spending will likely require additional financing, creating dilution and execution risk.
Weak Commercial ScaleVery low and inconsistent revenue combined with deeply negative gross and net margins shows that the business has not reached sustainable commercial scale. The cost structure remains disproportionate to sales, limiting visibility toward break-even.
Spectral Medical News
EDTXF FAQ
What was Spectral Medical’s price range in the past 12 months?
Spectral Medical lowest stock price was $0.81 and its highest was $1.27 in the past 12 months.
What is Spectral Medical’s market cap?
Spectral Medical’s market cap is $281.79M.
When is Spectral Medical’s upcoming earnings report date?
Spectral Medical’s upcoming earnings report date is Nov 06, 2026 which is in 70 days.
How were Spectral Medical’s earnings last quarter?
Spectral Medical released its earnings results on Aug 07, 2026. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$0.007 by $0.007.
Is Spectral Medical overvalued?
According to Wall Street analysts Spectral Medical’s price is currently Undervalued.
Does Spectral Medical pay dividends?
Spectral Medical pays a Notavailable dividend of $0.12 which represents an annual dividend yield of N/A. See more information on Spectral Medical dividends here
What is Spectral Medical’s EPS estimate?
Spectral Medical’s EPS estimate is >-0.01.
How many shares outstanding does Spectral Medical have?
Spectral Medical has 293,554,000 shares outstanding.
What happened to Spectral Medical’s price movement after its last earnings report?
Spectral Medical reported an EPS of $0 in its last earnings report, beating expectations of -$0.007. Following the earnings report the stock price went up 1.01%.
Which hedge fund is a major shareholder of Spectral Medical?
Currently, no hedge funds are holding shares in EDTXF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Spectral Medical
Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, Russia, and internationally. The company markets Endotoxin Activity Assay, a rapid in-vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B-Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops, manufactures, and markets monoclonal and polyclonal antibodies, recombinant cardiac proteins, antibodies, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was incorporated in 1991 and is headquartered in Toronto, Canada.
EDTXF Stock 12 Month Forecast
Average Price Target
$2.53
▲(163.32% Upside)
Technical Analysis
Cipher Pharmaceuticals
―
BioMark Diagnostics
―
―
Profound Medical
―
Sona Nanotech Inc
―
Ownership Overview
1.49% Insiders
<0.01% Other Institutional Investors
98.50% Public Companies and
Individual Investors